Pictet Asset Management
CYTK icon

Pictet Asset Management’s Cytokinetics CYTK Stock Holding History

Pictet Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99M Buy
1,160,463
+409,510
+55% +$29.4M 0.09% 232
2026
Q1 		$49.3M Sell
750,953
-6,610
-0.9% -$420K 0.05% 314
2025
Q4 		$48M Sell
757,563
-387,995
-34% -$24.1M 0.05% 332
2025
Q3 		$62.9M Sell
1,145,558
-400,833
-26% -$16.5M 0.06% 278
2025
Q2 		$51.1M Sell
1,546,391
-409,936
-21% -$14.3M 0.05% 312
2025
Q1 		$78.9M Buy
1,956,327
+44,328
+2% +$2.04M 0.09% 236
2024
Q4 		$89.9M Sell
1,911,999
-176,568
-8% -$9.17M 0.1% 215
2024
Q3 		$110M Buy
2,088,567
+320,405
+18% +$17.9M 0.12% 186
2024
Q2 		$95.8M Buy
1,768,162
+14,516
+0.8% +$876K 0.11% 195
2024
Q1 		$123M Buy
1,753,646
+381,402
+28% +$29.5M 0.13% 184
2023
Q4 		$115M Sell
1,372,244
-875,199
-39% -$31.7M 0.13% 186
2023
Q3 		$66.2M Buy
+2,247,443
New +$74.8M 0.08% 244

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's CYTK Position: Q2 2026 in Review

Pictet Asset Management increased its Cytokinetics (CYTK) stake by 55% in Q2 2026, buying an estimated $29.4M and bringing the position to 1,160,463 shares worth $99M. The position accounts for 0.09% of the portfolio, ranked #232.

Pictet Asset Management first reported a position in CYTK in Q3 2023 and has held it in 12 quarters since. The position peaked at $123M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Pictet Asset Management held 1,160,463 shares of Cytokinetics worth $99M as of Q2 2026.
  • Pictet Asset Management bought 409,510 Cytokinetics shares in Q2 2026, an estimated $29.4M.
  • Cytokinetics made up 0.09% of Pictet Asset Management's portfolio in Q2 2026, its #232 holding.
  • Pictet Asset Management first reported a position in Cytokinetics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Cytokinetics position peaked at $123M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.